Blocking the AR pathway in prostate cancer patients can be achieved by several mechanisms including surgical orchiectomy or chemically with luteinizing hormone-releasing hormone (LHRH) agonists, LHRH antagonists, or anti-androgens [27, 28]. This evidence concerns the gene GNRH1 and prostate carcinoma.